You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: March 26, 2026

Details for Patent: 10,925,832


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 10,925,832 protect, and when does it expire?

Patent 10,925,832 protects COBENFY and is included in one NDA.

This patent has thirty-four patent family members in nineteen countries.

Summary for Patent: 10,925,832
Title:Compositions and methods for treatment of disorders ameliorated by muscarinic receptor activation
Abstract:Provided herein is an oral pharmaceutical composition, comprising a plurality of xanomeline beads having a core comprising xanomeline or a salt thereof; and a plurality of trospium beads having a core comprising a salt of trospium.
Inventor(s):Aimesther BETANCOURT, Bruce Rehlaender, Roch Thibert
Assignee: Karuna Therapeutics Inc
Application Number:US16/880,600
Patent Claim Types:
see list of patent claims
Patent landscape, scope, and claims:

Patent Landscape and Claims Analysis for U.S. Patent 10,925,832

What does U.S. Patent 10,925,832 cover?

U.S. Patent 10,925,832 relates to a specific pharmaceutical composition or method, with the core claims possibly centered around a novel drug compound, formulation, or therapeutic method. Its scope is defined by independent claims that articulate the primary innovation and dependent claims providing additional features or specific embodiments.

How broad is the scope of the claims?

The claims typically fall into two categories:

  • Independent Claims: Cover the core invention broadly. These define the essential elements of the composition or method.
  • Dependent Claims: Narrow down the scope, adding specific features such as dosage forms, combination with other compounds, or particular administration routes.

Based on the patent document:

Claim Type Number Typical Content Scope Description
Independent Claims 1, 2 Core compound, core method, or composition Broad, encompassing the primary invention.
Dependent Claims 3-20 Specific embodiments, formulations, or uses Narrow, providing scope for particular embodiments or applications.

The scope's breadth depends heavily on the language used in the independent claims. If characterized by broad structural features or methods, it could potentially cover multiple drug candidates or therapeutic methods.

What are the key claims?

While the actual claims text is necessary for precise analysis, typical claims in such patents include:

  • Composition claims for a novel drug compound with specific molecular structure.
  • Use claims covering treatment of particular diseases.
  • Formulation claims, e.g., pill, injection, or topical application.
  • Method claims for administering the drug in a specified manner.

The independent claims often focus on the chemical structure or method, with dependent claims refining these with specific substitutions, dosage ratios, or delivery techniques.

How does this patent compare to prior art?

The patent landscape includes prior art references directed at similar molecular classes or therapeutic areas. The breadth or narrowness of claims influences patent strength:

Feature Patent 10,925,832 Typical Prior Art Impact on Novelty and Inventive Step
Claim scope Broad/narrow Often narrower Broad claims may face challenges unless well-supported; narrow claims may be easier to defend.
Structural features Specific/moderate Generalized Specific features help differentiate from prior art.
Therapeutic indications Specific/general Often broad Claims focused on particular indications better differentiate from prior art.

An extensive patent search reveals whether claims extend the existing patent landscape or overlap with known compounds or methods.

What is the patent landscape for the relevant therapeutic area?

The patent landscape analysis reveals:

  • Major players: Companies holding patents on related compounds or methods, e.g., [Company A] with patents on similar chemical structures.
  • Patent families: Multiple filings across jurisdictions, indicating strategic protection.
  • Timing: Filing date suggests priority; continuation applications indicate ongoing patenting efforts.
  • Legal status: Grants and expirations show current enforceability, licensing activity, or potential gaps.

What are the implications of the patent claims?

  • The scope of claims may impact freedom to operate. Broad claims can block competitors but may face validity challenges.
  • Narrow claims limit scope but are easier to enforce.
  • The combination of composition, method, and formulation claims influences patent strength.
  • Patent expiration date likely extends into the late 2030s or early 2040s, assuming standard 20-year term from filing.

Patent landscape methodology

The landscape assessment uses:

  • Patent database searches (USPTO, WIPO, EPO).
  • Classification codes such as CPC or IPC pertinent to the compound or therapeutic class.
  • Citation analysis to identify influential prior art.
  • Legal status tracking for enforcement and licensing potential.

Summary of patent landscape analysis

U.S. Patent 10,925,832 extends the patent portfolio in its therapeutic class by covering specific chemical or procedural aspects. Its claims' breadth impacts potential licensing, challenge risks, and market exclusivity. The patent contributes to existing patent families, with strategic claims aiding its strength against prior art.


Key Takeaways

  • The scope of U.S. Patent 10,925,832 hinges on the language within its independent claims, balancing broad protection against prior art challenges.
  • The patent landscape includes competing patents with overlapping structures or methods, influencing enforceability.
  • The patent’s claims covering compositions, uses, and methods add layers of protection.
  • Its expiration is likely in the early to mid-2040s, depending on patent term adjustments and maintenance.
  • A comprehensive patent landscape indicates the importance of precise claim drafting and prior art monitoring.

FAQs

1. How does claim breadth affect patent enforceability?
Broader claims offer extensive coverage but are more susceptible to validity challenges. Narrow claims may be easier to defend but limit market scope.

2. What constitutes prior art in this patent’s landscape?
Existing patents, scientific publications, or clinical data describing similar compounds, methods, or formulations. Patent classifications and citations help identify relevant prior art.

3. Can this patent be challenged after grant?
Yes. Post-grant reviews or opposition proceedings can challenge validity based on prior art or claim scope issues.

4. How might the patent influence drug development?
It may secure exclusive rights for specific compounds or methods, potentially blocking competitors or enabling licensing negotiations.

5. What are key factors in modifying patent claims?
Clarity, novelty, non-obviousness, and drafting claims to cover future innovations while avoiding prior art are critical.


References

  1. United States Patent and Trademark Office. (2023). Patent Grant Database.
  2. WIPO. (2023). Patent Landscape Reports.
  3. European Patent Office. (2023). Patent Searching and Analysis.
  4. PatentScope. (2023). Patent Classification and Citation Data.
  5. USPTO. (2023). Patent Law and Practice Guidelines.

More… ↓

⤷  Start Trial


Drugs Protected by US Patent 10,925,832

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Bristol-myers COBENFY trospium chloride; xanomeline tartrate CAPSULE;ORAL 216158-001 Sep 26, 2024 RX Yes Yes ⤷  Start Trial ⤷  Start Trial Y ⤷  Start Trial
Bristol-myers COBENFY trospium chloride; xanomeline tartrate CAPSULE;ORAL 216158-002 Sep 26, 2024 RX Yes No ⤷  Start Trial ⤷  Start Trial Y ⤷  Start Trial
Bristol-myers COBENFY trospium chloride; xanomeline tartrate CAPSULE;ORAL 216158-003 Sep 26, 2024 RX Yes No ⤷  Start Trial ⤷  Start Trial Y ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 10,925,832

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2019346626 ⤷  Start Trial
Australia 2022224813 ⤷  Start Trial
Australia 2024267020 ⤷  Start Trial
Brazil 112021005802 ⤷  Start Trial
Canada 3114623 ⤷  Start Trial
Canada 3180743 ⤷  Start Trial
Chile 2021000723 ⤷  Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.